Search results
This ESMO Clinical Practice Guideline provides key recommendations for managing gastric cancer. The guideline covers clinical and pathological diagnosis, staging and risk assessment, treatment and follow-up. Treatment and management algorithms for localised and advanced/metastatic disease are provided.
Stomach cancer (also known as gastric cancer) is a type of cancer that develops in the stomach, which is part of the digestive system. Stomach cancer can develop in any part of the stomach, but most begin in the gland cells of the inner stomach lining. These stomach cancers are called adenocarcinomas. This guide is focused on adenocarcinomas.
Stomach cancer (also known as gastric cancer) is a type of cancer that develops in the stomach, which is part of the digestive system. The stomach is connected to the oesophagus at the top and the duodenum at the bottom, and produces gastric juice, which breaks down food so the body can absorb it. Anatomy of the stomach.
ESMO has Clinical Practice Guidelines on the following Gastrointestinal Cancers: Rectal Cancer, Biliary cancer, Gastric cancer, Oesophageal cancer, Pancreatic cancer, Metastatic colorectal cancer, Anal cancer, Early colon cancer, Familial risk colorectal cancer, Hepatocellular carcinoma. They include information on incidence, diagnosis, staging ...
With stomach cancer, a vital first step is to assess how deeply the cancer has invaded the lining and wall of the stomach. As with all tumours, the approach to therapy will also depend on whether the cancer has spread from the stomach to nearby lymph nodes and perhaps to sites elsewhere in the body. Distant spread of a tumour is termed metastasis.
The tiered approach of ESMO in delivering a guidance for cancer patients during the COVID-19 pandemic is designed across three levels of priorities, namely: tier 1 (high priority intervention), 2 (medium priority) and 3 (low priority) – defined according to the criteria of the Cancer Care Ontario, Huntsman Cancer Institute and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS), incorporating the information on the value-based prioritisation and clinical cogency of the interventions
Dec 14, 2023 · Gastric Cancer; Gastro-Oesophageal Junction Cancer On 16 November 2023, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma.
Nov 23, 2022 · There is an unmet medical need for treatments of HER2-low gastric or gastroesophageal junction cancer. Trastuzumab deruxtecan improved overall response rate (ORR) and overall survival (OS) versus physician's choice of chemotherapy in patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma who had progressed on a trastuzumab-containing regimen in primary analysis of the DESTINY-Gastric01 study.
Jun 28, 2023 · The ESMO World Congress on Gastrointestinal Cancer 2023 took place on 28 June – 1 July 2023 in Barcelona, Spain. The congress was the place where oncology, pathology, and hepatology experts, clinicians, and surgeons, as well as clinical researchers from across the globe came to share pioneering research, approaches, and best practices in treating patients with cancers of the gastrointestinal tract.
Jan 29, 2024 · Date: 29 Jan 2024. Overweight and obesity are contributing to rising death rates from bowel cancer among people aged 25-49 years in the European Union (EU) and the UK, although death rates from this type of cancer are decreasing overall across Europe. These findings are from a new study published in the leading cancer journal Annals of Oncology ...
